Global epidemiology of amyloid light-chain amyloidosis.
Amyloid light-chain amyloidosis
Epidemiology
Global
Incidence
Prevalence
Rare disease
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
19 07 2022
19 07 2022
Historique:
received:
04
02
2022
accepted:
26
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Amyloid light-chain (AL) amyloidosis is an ultra-rare disease associated with significant morbidity and mortality. Few studies have examined the global epidemiology of this condition. This study estimated the diagnosed incidence and 1-year, 5-year, 10-year, and 20-year period prevalence of AL amyloidosis in 2018 for countries in and near Europe, and in the United States (US), Canada, Brazil, Japan, South Korea, Taiwan, and Russia. A systematic literature review (SLR) was conducted to identify country-specific, age- and gender-specific diagnosed incidence of AL amyloidosis and observed survival data-point inputs for an incidence-to-prevalence model. Extrapolations were used to estimate incidence and prevalence for countries without registry or published epidemiological data. Of 171 publications identified in the SLR, 10 records met the criteria for data extraction, and two records were included in the final incidence-to-prevalence model. In 2018, an estimated 74,000 AL amyloidosis cases worldwide were diagnosed during the preceding 20 years. The estimated incidence and 20-year prevalence rates were 10 and 51 cases per million population, respectively. Orphan medicinal product designation criteria of the European Medicines Agency or Electronic Code of Federal Regulations indicate that a disease must not affect > 5 in 10,000 people across the European Union or affect < 200,000 people in the US. This study provides up-to-date epidemiological patterns of AL amyloidosis, which is vital for understanding the burden of the disease, increasing awareness, and to further research and treatment options.
Sections du résumé
BACKGROUND
Amyloid light-chain (AL) amyloidosis is an ultra-rare disease associated with significant morbidity and mortality. Few studies have examined the global epidemiology of this condition.
METHODS
This study estimated the diagnosed incidence and 1-year, 5-year, 10-year, and 20-year period prevalence of AL amyloidosis in 2018 for countries in and near Europe, and in the United States (US), Canada, Brazil, Japan, South Korea, Taiwan, and Russia. A systematic literature review (SLR) was conducted to identify country-specific, age- and gender-specific diagnosed incidence of AL amyloidosis and observed survival data-point inputs for an incidence-to-prevalence model. Extrapolations were used to estimate incidence and prevalence for countries without registry or published epidemiological data.
RESULTS
Of 171 publications identified in the SLR, 10 records met the criteria for data extraction, and two records were included in the final incidence-to-prevalence model. In 2018, an estimated 74,000 AL amyloidosis cases worldwide were diagnosed during the preceding 20 years. The estimated incidence and 20-year prevalence rates were 10 and 51 cases per million population, respectively.
CONCLUSIONS
Orphan medicinal product designation criteria of the European Medicines Agency or Electronic Code of Federal Regulations indicate that a disease must not affect > 5 in 10,000 people across the European Union or affect < 200,000 people in the US. This study provides up-to-date epidemiological patterns of AL amyloidosis, which is vital for understanding the burden of the disease, increasing awareness, and to further research and treatment options.
Identifiants
pubmed: 35854312
doi: 10.1186/s13023-022-02414-6
pii: 10.1186/s13023-022-02414-6
pmc: PMC9295439
doi:
Types de publication
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
278Informations de copyright
© 2022. The Author(s).
Références
Blood. 2019 Jan 17;133(3):215-223
pubmed: 30333122
J Clin Oncol. 2004 Sep 15;22(18):3751-7
pubmed: 15365071
Acta Haematol. 2020;143(4):304-311
pubmed: 32340017
Blood. 2020 Dec 3;136(23):2620-2627
pubmed: 33270858
Leukemia. 2022 Jan;36(1):225-235
pubmed: 34168284
Rheum Dis Clin North Am. 2013 May;39(2):323-45
pubmed: 23597967
Blood Cancer J. 2021 May 15;11(5):90
pubmed: 33993188
Blood. 2017 Apr 13;129(15):2111-2119
pubmed: 28126928
Adv Ther. 2015 Oct;32(10):920-8
pubmed: 26498944
Br J Haematol. 2013 May;161(4):525-32
pubmed: 23480608
Blood. 2013 Apr 25;121(17):3420-7
pubmed: 23479568
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953
BMC Public Health. 2012 Nov 13;12:974
pubmed: 23148499
JACC Heart Fail. 2019 Nov;7(11):958-966
pubmed: 31606365
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Nat Rev Dis Primers. 2018 Oct 25;4(1):38
pubmed: 30361521
Blood Cancer J. 2021 May 18;11(5):97
pubmed: 34006856
J Comp Eff Res. 2018 Jun;7(6):549-559
pubmed: 29390860
Blood. 2015 Jul 30;126(5):612-5
pubmed: 25987656
Amyloid. 2016 Sep;23(3):184-187
pubmed: 27470486
Mayo Clin Proc. 2017 Jun;92(6):908-917
pubmed: 28483059
Blood Adv. 2018 May 22;2(10):1046-1053
pubmed: 29748430
Curr Med Res Opin. 2017 Jun;33(6):1017-1031
pubmed: 28277869
Blood. 2020 Jul 2;136(1):71-80
pubmed: 32244252
Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1074-8
pubmed: 19210872
Orphanet J Rare Dis. 2017 Sep 6;12(1):152
pubmed: 28877709
Clin Kidney J. 2015 Feb;8(1):120-6
pubmed: 25713722